Valuation: Tonix Pharmaceuticals Holding Corp

Market Cap 204M 179M 165M 152M 289M 19.51B 295M 1.98B 771M 9.55B 765M 748M 33.14B P/E 2026 *
-1.24x
P/E 2027 * -2.06x
Enterprise Value 204M 179M 165M 152M 289M 19.51B 295M 1.98B 771M 9.55B 765M 748M 33.14B EV / Sales 2026 *
5.96x
EV / Sales 2027 * 2.58x
Free-Float
99.87%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tonix Pharmaceuticals Holding Corp

Manager TitleAgeSince
Chief Executive Officer 68 16/11/2007
Director of Finance/CFO 52 01/02/2016
Chief Tech/Sci/R&D Officer 57 04/02/2025
Director TitleAgeSince
Chairman 68 01/10/2011
Director/Board Member 66 12/09/2017
Director/Board Member 81 05/09/2018
Change 5-day change 1-year change 3-year change Capi.($)
+83.42%-17.57% - - 204M
-1.60%+2.02%+56.34%+168.94% 1,084B
-1.44%+3.71%+69.07%+65.40% 634B
-0.75%+0.67%+33.18%+86.52% 447B
-1.35%+1.86%+29.96%+26.28% 330B
-0.86%+2.79%+37.72%+40.85% 295B
-0.71%+0.72%+28.85%+48.27% 285B
-1.31%-0.26%-28.18%-39.82% 218B
-0.03%+1.84%+23.90%+68.30% 199B
-0.40%+7.82%+22.29%+82.50% 169B
Average +7.50%+2.52%+30.35%+60.81% 406.65B
Weighted average by Cap. -1.15%+2.48%+41.34%+86.49%

Financials

2026 *2027 *
Net sales 34.18M 29.98M 27.68M 25.58M 48.48M 3.27B 49.46M 333M 129M 1.6B 128M 126M 5.56B 78.93M 69.23M 63.92M 59.07M 112M 7.56B 114M 768M 299M 3.7B 296M 290M 12.84B
Net income -170M -149M -138M -127M -241M -16.27B -246M -1.65B -643M -7.96B -638M -624M -27.65B -152M -133M -123M -114M -215M -14.54B -220M -1.48B -574M -7.11B -570M -558M -24.7B
Net Debt - -
Logo Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing and commercializing therapeutics to treat and vaccines to prevent, disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-